Search

Your search keyword '"Stocco, Gabriele"' showing total 518 results
Start Over Author "Stocco, Gabriele"
518 results on '"Stocco, Gabriele"'

58. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile

Author

Sorich, Michael J., Pottier, Nicolas, Pei, Deqing, Yang, Wenjian, Kager, Leo, Stocco, Gabriele, Cheng, Cheng, Panetta, John C., Pui, Ching-Hon, Relling, Mary V., Cheok, Meyling H., and Evans, William E.

Abstract

Introduction Childhood acute lymphoblastic leukemia (ALL), the most common cancer in children, can now be cured in approximately 80% of patients [1,2]. Pharmacogenomics aims to elucidate the genomic determinants of [...], Background Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients. Nevertheless, drug resistance is the major cause of treatment failure in children with ALL. The drug methotrexate (MTX), which is widely used to treat many human cancers, is used in essentially all treatment protocols worldwide for newly diagnosed ALL. Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells. This lack of knowledge is due in part to the fact that existing in vitro methods are not sufficiently reliable to permit assessment of MTX resistance in primary ALL cells. Therefore, we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX. Methods and Findings We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial 'up-front' in vivo MTX treatment (1 g/[m.sup.2]) to elucidate interpatient differences in the antileukemic effects of MTX. To identify genomic determinants of these effects, we performed a genome-wide assessment of gene expression in primary ALL cells from 161 of these newly diagnosed children (1-18 y). We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX. This finding was validated in an independent cohort of children with ALL. Furthermore, this measure of initial MTX in vivo response and the associated gene expression pattern were predictive of long-term disease-free survival (p < 0.001, p = 0.02). Conclusions Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL. Trial registrations: Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101 D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).

Published
2008

64. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity

Author

Stocco, Gabriele, Yang, Wenjian, Crews, Kristine R., Thierfelder, William E., Decorti, Giuliana, Londero, Margherita, Franca, Raffaella, Rabusin, Marco, Valsecchi, Maria Grazia, Pei, Deqing, Cheng, Cheng, Paugh, Steven W., Ramsey, Laura B., Diouf, Barthelemy, McCorkle, Joseph Robert, Jones, Terreia S., Pui, Ching-Hon, Relling, Mary V., and Evans, William E.

Published
2012
Full Text
View/download PDF

66. Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients

Author

Lucafò, Marianna, primary, Granata, Simona, additional, Bonten, Erik J., additional, McCorkle, Robert, additional, Stocco, Gabriele, additional, Caletti, Chiara, additional, Selvestrel, Davide, additional, Cozzarolo, Alessio, additional, Zou, Chan, additional, Cuzzoni, Eva, additional, Pasini, Andrea, additional, Montini, Giovanni, additional, Gambaro, Giovanni, additional, Decorti, Giuliana, additional, Evans, William, additional, and Zaza, Gianluigi, additional

Published
2021
Full Text
View/download PDF

74. Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients

Author

Genova, Elena, primary, Cavion, Federica, additional, Lucafò, Marianna, additional, Pelin, Marco, additional, Lanzi, Gaetana, additional, Masneri, Stefania, additional, Ferraro, Rosalba Monica, additional, Fazzi, Elisa Maria, additional, Orcesi, Simona, additional, Decorti, Giuliana, additional, Tommasini, Alberto, additional, Giliani, Silvia, additional, and Stocco, Gabriele, additional

Published
2020
Full Text
View/download PDF

77. Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants

Author

Lunenburg, Carin A. T. C., Henricks, Linda M., van Kuilenburg, André, Mathijssen, Ron H. J., Schellens, Jan H. M., Gelderblom, Hans, Guchelaar, Henk-Jan, Swen, Jesse J., Cecchin, Erika, Stocco, Gabriele, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, Amsterdam Gastroenterology Endocrinology Metabolism, and Laboratory Genetic Metabolic Diseases

Published
2020

80. Association of Bc/I polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease

Author

Iudicibus, Sara De, Stocco, Gabriele, Martelossi, Stefano, Drigo, Ilenia, Norbedo, Stefania, Lionetti, Paolo, Pozzi, Elena, Barabino, Arrigo, Decorti, Giuliana, Bartoli, Fiora, and Ventura, Alessandro

Subjects
Inflammatory bowel diseases -- Drug therapy, Corticosteroids -- Dosage and administration, Corticosteroids -- Health aspects, Genetic polymorphisms -- Physiological aspects, Health
Published
2007

83. Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD

Author

Lucafò, Marianna, primary, Pugnetti, Letizia, additional, Bramuzzo, Matteo, additional, Curci, Debora, additional, Di Silvestre, Alessia, additional, Marcuzzi, Annalisa, additional, Bergamo, Alberta, additional, Martelossi, Stefano, additional, Villanacci, Vincenzo, additional, Bozzola, Anna, additional, Cadei, Moris, additional, De Iudicibus, Sara, additional, Decorti, Giuliana, additional, and Stocco, Gabriele, additional

Published
2019
Full Text
View/download PDF

87. Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants

Author

Lucafò, Marianna, primary, Stocco, Gabriele, additional, Martelossi, Stefano, additional, Favretto, Diego, additional, Franca, Raffaella, additional, Malusà, Noelia, additional, Lora, Angela, additional, Bramuzzo, Matteo, additional, Naviglio, Samuele, additional, Cecchin, Erika, additional, Toffoli, Giuseppe, additional, Ventura, Alessandro, additional, and Decorti, Giuliana, additional

Published
2019
Full Text
View/download PDF

88. Ekspresioni obrazac duge nekodirajuće RNK growth arrest specific 5 u fazi indukcije u terapiji dečje akutne limfoblastne leukemije

Author

Gašić, Vladimir, Stanković, Biljana, Zukić, Branka, Janić, Dragana, Dokmanović, Lidija, Krstovski, Nada, Lazić, Jelena, Milošević, Goran, Lucafò, Marianna, Stocco, Gabriele, Decorti, Giuliana, Pavlović, Sonja, Kotur, Nikola, Gašić, Vladimir, Stanković, Biljana, Zukić, Branka, Janić, Dragana, Dokmanović, Lidija, Krstovski, Nada, Lazić, Jelena, Milošević, Goran, Lucafò, Marianna, Stocco, Gabriele, Decorti, Giuliana, Pavlović, Sonja, and Kotur, Nikola

Abstract

Uvod: Ekspresija duge nekodirajuće RNK G AS5 je izme - njena u mnogim kancerima zbog njene uloge u apoptozi i inhibiciji rasta ćelije. G AS5 interaguje sa glukokortikoidnim receptorom, što je čini potencijalnim farmakotranskripcionim markerom značajnim za glukokortikoidnu terapiju. Naš cilj u ovoj studiji je bio da analiziramo ekspresiju GAS5 tokom indukcione terapije kod dečje akutne limfoblastne leukemije (ALL), u kojoj se koriste glukokortikoidni lekovi, i da te rezultate povežemo sa odgovorom na terapiju. Metode: Nivo ekspresije G AS5 u mononuklearnim ćelijama periferne krvi izolovanih od 29 dece obolelih od ALL, određen je metodologijom RT-qPCR, i to u momentu dijagnoze, 15. i 33. dana indukcione terapije. Rezultati: Naši rezultati su pokazali da postoje interindivi - dualne razlike u ekspresiji GAS5 kod pacijenata, i to u svim analiziranim tačkama. Kod svakog ALL pacijenta GAS5 ekspresija je 15. dana bila visa u odnosu na ekspresiju u momentu dijagnoze (p lt 0,0005). Nivo ekspresije GAS5 je 33. dana bio niži u poređenju sa 15. danom (p lt 0,0005), ali je i dalje bio značajno visi u odnosu na momenat dijagnoze kod većine pacijenata (p = 0,001). Pacijenti čiji je broj blasta u perifernoj krvi 8. dana bio ispod 100 po mikrolitru periferne krvi, imali su viši nivo ekspresije GAS5 (p = 0,016) i niži odnos ekspresija merenih 15. dana i u momentu dijagnoze (p = 0,009). Zaključak: Nasi rezultati ukazuju da bi nivo ekspresije GAS5 mogao da bude marker terapijskog odgovora u indukcionoj terapiji kod dece obolele od ALL., Background: Long non-coding RNA growth arrest-specific 5 (GAS5) is deregulated in many cancers because of its role in cell growth arrest and apoptosis. Additionally, GAS5 interacts with glucocorticoid receptor, making it a potential pharmacotranscription marker of glucocorticoid (GC) therapy. In this study, we aimed at analysing G AS5 expression in the remission induction therapy phase of childhood acute lymphoblastic leukemia (ALL), in which GCs are mandatorily used, and to correlate it with therapy response. Methods: G AS5 expression was measured in peripheral blood mononuclear cells taken from 29 childhood ALL patients at diagnosis, on day 15 and day 33 of remission induction therapy using RT-qPCR methodology. Results: Our results have shown interindividual differences in G AS5 expression at all time points. For each ALL patient, G A S5 expression was higher on day 15 in comparison to its level at diagnosis (p lt 0.0005). On day 33, the level of G A S5 expression decreased in comparison with day 15 (p lt 0.0005), but it was still significantly higher than at diagnosis for the majority of patients (p=0.001). Patients whose number of blasts on day 8 was below 100 per mL of peripheral blood had a higher GAS5 expression at diagnosis (p=0.016), and lower ratio day 15/diagnosis (p=0.009). Conclusions: Our results suggest that the expression level of GAS5 could be a potential marker of therapy response in remission induction therapy of childhood ALL.

Published
2019

90. Effect of periodontal therapy on the course of cyclosporin-induced gingival overgrowth: role of ABCB1 and PAI-1 gene polymorphisms.

Author

De Iudicibus, Sara, Stocco, Gabriele, Castronovo, Gaetano, Pico, Camillo, Racano, Roberto, Borelli, Massimo, Bevilacqua, Lorenzo, Di Lenarda, Roberto, Bartoli, Fiora, and Decorti, Giuliana

Subjects
CONFIDENCE intervals, GENETIC polymorphisms, HEALTH outcome assessment, PERIODONTAL disease, POLYMERASE chain reaction, SCALES (Weighing instruments), STATISTICS, DATA analysis, TREATMENT effectiveness, PRE-tests & post-tests, REPEATED measures design, DATA analysis software, CYCLOSPORINS, DESCRIPTIVE statistics
Abstract

Objectives: Etiological periodontal therapy is effective in reducing cyclosporin A-induced gingival overgrowth, but a high variability among subjects has been observed. This study aimed to evaluate the role of polymorphisms in PAI-1 and A BCB1 genes on the course of this side effect following periodontal therapy. Method and Materials: Forty-five transplant patients were subjected to nonsurgical periodontal therapy and evaluated for hypertrophy index, probing depths, bleeding, and plaque scores at baseline, and after 3 and 6 months. A BCB1 (C3435T and G2677T) and PAI-1 (4G/5G) polymorphisms were studied with polymerase chain reaction-restriction fragment length polymorphism and allele-specific polymerase chain reaction respectively. Results: All the monitored periodontal indexes decreased significantly during the six months. Modeling of hypertrophy index by linearmixed- effect models (allowing non-normal distribution of the outcome variable hypertrophy index) resulted in the selection as the most significant model, of the one comprising the independent variables: time, C 3435T genotype, and their interaction term. This model indicated that C 3435T-mutated patients had significantly higher baseline hypertrophy index values (90% Markov chain Monte Carlo empirical confidence intervals: 5.08, 30.00). The decrease in hypertrophy index values over time showed a trend toward being faster in mutated than nonmutated patients (interaction time: C 3435T nonmutated, 90% Markov chain Monte Carlo empirical confidence interval: -11.08, -0.40). When hypertrophy index values were normalized, the significance and trend were lost. No effect of the A BCB1 G2677T and PAI-1 4G/5G polymorphisms was observed.Conclusion: These preliminary results suggest that C 3435T polymorphism is a genetic factor that could influence the course of cyclosporin A-induced gingival overgrowth in transplant patients subjected to periodontal therapy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

91. Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients.

Author

Lucafò, Marianna, Franzin, Martina, Lagatolla, Cristina, Franca, Raffaella, Bramuzzo, Matteo, Stocco, Gabriele, and Decorti, Giuliana

Subjects
GUT microbiome, ANTINEOPLASTIC agents, INFLAMMATORY bowel diseases, JUVENILE idiopathic arthritis, IMMUNOLOGIC diseases, IMMUNOSUPPRESSIVE agents
Abstract

Diseases affecting the immune system, such as inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and acute lymphoblastic leukemia (ALL), are pathological conditions affecting the pediatric population and are often associated with alterations in the intestinal microbiota, such as a decrease in bacterial diversity. Growing evidence suggests that gut microbiota can interfere with chemotherapeutic and immunosuppressant drugs, used in the treatment of these diseases, reducing or facilitating drug efficacy. In particular, the effect of intestinal microflora through translocation, immunomodulation, metabolism, enzymatic degradation, and reduction of bacterial diversity seems to be one of the reasons of interindividual variability in the therapeutic response. Although the extent of the role of intestinal microflora in chemotherapy and immunosuppression remains still unresolved, current evidence on bacterial compositional shifts will be taken in consideration together with clinical response to drugs for a better and personalized therapy. This review is focused on the effect of the intestinal microbiota on the efficacy of pharmacological therapy of agents used to treat IBD, JIA, and ALL. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

99. High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients

Author

De Iudicibus, Sara, primary, Lucafò, Marianna, additional, Vitulo, Nicola, additional, Martelossi, Stefano, additional, Zimbello, Rosanna, additional, De Pascale, Fabio, additional, Forcato, Claudio, additional, Naviglio, Samuele, additional, Di Silvestre, Alessia, additional, Gerdol, Marco, additional, Stocco, Gabriele, additional, Valle, Giorgio, additional, Ventura, Alessandro, additional, Bramuzzo, Matteo, additional, and Decorti, Giuliana, additional

Published
2018
Full Text
View/download PDF

100. Imidazo[2,1-b]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor

Author

Christodoulou, Michael S., primary, Dapiaggi, Federico, additional, Ghiringhelli, Francesca, additional, Pieraccini, Stefano, additional, Sironi, Maurizio, additional, Lucafò, Marianna, additional, Curci, Debora, additional, Decorti, Giuliana, additional, Stocco, Gabriele, additional, Chirumamilla, Chandra Sekhar, additional, Vanden Berghe, Wim, additional, Balaguer, Patrick, additional, Michel, Benoît Y., additional, Burger, Alain, additional, Beccalli, Egle M., additional, Passarella, Daniele, additional, and Martinet, Nadine, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results